If you'd invested in: Nanoco and Nostrum

Manchester-based tech company Nanoco is flying, while oil producer Nostrum has had a bad year.

If only...

926_Good

Nanoco (LSE: NANO) is a Manchester-based tech company developing the future of nanotechnology. It is working on quantum dots (tiny semiconductor particles) to improve everything from bio-imaging to the colours of LCD displays on your computer, TV or smartphone. "We've worked really hard to keep all costs within the business down," chief executive Dr Michael Edelman said after announcing a £2m rise in the group's cash position in the first and second quarter. Nanoco grew its revenues 150% last year and the stock has gained 50% in 12 months.

Be glad you didn't buy...

926_Bad

Nostrum (LSE: NOG) explores and produces oil and gas in the Pre-Caspian Basin of western Kazakhstan. The company hit trouble earlier this year when it faced "unexpected challenges", with water flowing into the wells along its gas-producing reservoir. Volatility in global oil prices has made matters worse. Nostrum announced plans last week to reduce the number of active drilling rigs from three to two. The past year has seen the share price slump by 63% as the group made a loss of $23.8m, while net debt has climbed above $1bn.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Explore More
Madeleine Taylor

Madeleine is a journalist in based in Tokyo. She is a former contributor for MoneyWeek, covering  stock markets, art and travel, and is a former investment writer for The Financial Times. Her work has appeared in titles including The Week, Investors Chronicle and the NME.